# Lapatinib in Stage IV Melanoma With ERBB4 Mutations

> **NCT01264081** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT01264081
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05-20
- **Primary completion:** 2013-11-22
- **Final completion:** 2013-11-22
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Protocol would not be able to reach stated accrual.
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01264081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01264081, "Lapatinib in Stage IV Melanoma With ERBB4 Mutations". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01264081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*